

# 1 **Chikungunya virus antepartum transmission and abnormal infant outcomes** 2 **in Nigeria**

3  
4 Atiene S. Sagay<sup>1,a</sup>, Szu-Chia Hsieh<sup>2,a</sup>, Yu-Ching Dai<sup>2,a</sup>, Charlotte Ajeong Chang<sup>3</sup>, Jerry  
5 Ogwuche<sup>4</sup>, Olukemi O. Ige<sup>1</sup>, Makshwar L. Kahansim<sup>1</sup>, Beth Chaplin<sup>3</sup>, Godwin Imade<sup>1</sup>, Michael  
6 Elujoba<sup>4</sup>, Michael Paul<sup>1</sup>, Donald J. Hamel<sup>3</sup>, Hideki Furuya<sup>5</sup>, Ricardo Khoury<sup>6</sup>, Viviane Sampaio  
7 Boaventura<sup>6</sup>, Laíse de Moraes<sup>6</sup>, Phyllis J. Kanki<sup>3</sup>, Wei-Kung Wang<sup>2</sup>

8  
9 <sup>1</sup>Jos University Teaching Hospital, University of Jos, Jos, Nigeria;

10 <sup>2</sup>Department of Tropical Medicine, Medical Microbiology and Pharmacology, John A. Burns  
11 School of Medicine, University of Hawaii at Manoa, Honolulu, Hawaii, USA;

12 <sup>3</sup>Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public  
13 Health, Boston, Massachusetts, USA; <sup>4</sup>Our Lady of Apostles Hospital, Jos, Nigeria

14 <sup>5</sup>Department of Biomedical Science, Cedars-Sinai Medical Center, Los Angeles, California,  
15 USA;

16 <sup>6</sup>Instituto Gonçalo Moniz –Oswaldo Cruz Foundation (FIOCRUZ), Bahia, Brazil

17  
18 **Correspondence:** Wei-Kung Wang (wangwk@hawaii.edu) and Phyllis J. Kanki  
19 (pkanki@hsph.harvard.edu),

20 <sup>a</sup>These authors contributed equally.

21  
22 **Keywords.** chikungunya virus; arbovirus ; pregnancy ; perinatal transmission ; congenital  
23 abnormality ; Africa ; Nigeria

## 24 25 **ABSTRACT**

26 Chikungunya virus (CHIKV) has become a global public health concern since the reemergence  
27 of the Indian Ocean lineage and expansion of the Asian genotype. CHIKV infection causes acute  
28 febrile illness, rash, and arthralgia and during pregnancy may affect both mothers and infants.  
29 The mother-to-child transmission (MTCT) of CHIKV in Africa remains understudied. We  
30 screened 1006 pregnant women at two clinics in Nigeria between 2019 and 2022 and  
31 investigated the prevalence and MTCT of CHIKV. Of the 1006, 119 tested positive for CHIKV  
32 IgM, of which 36 underwent detailed laboratory tests. While none of the IgM reactive samples  
33 were RT-PCR positive, 14 symptomatic pregnant women were confirmed by CHIKV  
34 neutralization test. Twelve babies were followed with 8 normal and 4 abnormal outcomes,  
35 including stillbirth, cleft lip/palate with microcephaly, preterm delivery, polydactyly with sepsis  
36 and jaundice. CHIKV IgM testing identified 3 antepartum transmissions, further studies will  
37 determine its impact in antepartum infection.

## 38 **Introduction**

39 Chikungunya virus (CHIKV), a member of the genus *Alphavirus* of the family *Togaviridae*, is  
40 transmitted by *Aedes aegypti* and *Aedes albopictus* mosquitoes. Prior to 2005, there were 3  
41 distinct genotypes of CHIKV: the East-Central-South African (ECSA), West African and Asian  
42 genotypes in different geographic locations (1-3). The ECSA genotype spread from East Africa  
43 to the Indian Ocean and Asia between 2004-2007, known as the Indian Ocean lineage (IOL). In  
44 addition, the Asian genotype expanded in late 2013, the so-called the Asian-Western Hemisphere  
45 lineage, leading to its spread in the Americas with over 1.3 million suspected cases by April  
46 2015 (1-3). It has been reported that autochthonous transmission of CHIKV occurs in 114  
47 countries and territories over the tropical and sub-tropical areas of Africa, Asia, Oceania, the  
48 Americas, and Europe, where greater than three quarters of the world's population reside (1-3).

49 CHIKV in Africa is maintained in an enzootic cycle involving non-human primates and  
50 sylvatic *Aedes* mosquitoes; sporadic cases or outbreaks tend to be small-scaled and associated  
51 with spillover from the natural reservoir vectors or environmental conditions such as increased  
52 rainfall (4-6). Recently, an increase in larger-scale outbreaks associated with urban areas of  
53 Africa have been reported (2,7,8).

54 CHIKV infection causes acute febrile illness, rash and arthralgia and may affect both  
55 pregnancy and infant outcomes (9,10). During the Reunion Island outbreak in 2005, the  
56 prospective study of CHIKV infection in pregnancy described mother-to-child transmission  
57 (MTCT) was observed in viremic mothers during the intrapartum period (within 2 days prior to  
58 and after delivery) with a transmission rate of 48.7%, leading to neonatal disease with sepsis-like  
59 illness, encephalitis, convulsions, and death (11-13). The study also described 3 exceptional  
60 cases of early fetal deaths (before 22 weeks) out of 678 antepartum CHIKV infections which

61 were attributed to intrauterine CHIKV infection. As CHIKV spread from Asia to the Americas  
62 between 2007-2014, perinatal transmission of CHIKV was reported in India, Colombia, Brazil,  
63 and Curacao (14-17). Meta-analysis of cohort studies from Asia and Latin America revealed a  
64 MTCT rate of 15.5% with symptomatic neonatal disease attributed to intrapartum infection  
65 (10,18,19). However, the MTCT of African strains of CHIKV remains poorly understood.

66 In this study, we screened 1006 pregnant women at two antenatal clinics in Jos, north-central  
67 Nigeria from April 2019 to January 2022. We investigated the prevalence of CHIKV infection  
68 among pregnant women, transmission, and disease outcome in infants.

## 69 **Methods**

### 70 **Nigeria cohort and human samples**

71 Between April 1, 2019 and January 31, 2022, pregnant women aged  $\geq 18$  years, who attended the  
72 antenatal clinics at Jos University Teaching Hospital (JUTH) and Our Lady of Apostles Hospital  
73 (OLA) in Jos, north-central Nigeria, and presented with fever ( $\geq 37.5^\circ\text{C}$ ) or other symptoms  
74 (rash, headache, arthralgia, conjunctivitis, or myalgia) in the past 3 days were recruited with  
75 informed consent for screening by the Chembio DPP<sup>®</sup> ZCD IgM/IgG rapid test (Chembio  
76 Diagnostics Inc. Medford, NY). For every four symptomatic women, one asymptomatic woman  
77 with gestational age (GA) within two weeks of any of the four symptomatic women was also  
78 recruited for screening. All ZIKV, DENV or CHIKV rapid test IgM and IgM/IgG reactive  
79 women were recruited with informed consent for the prospective observational study as  
80 described (20). The pregnant women with CHIKV infection (CHIKV IgM+ and/or IgG+) and  
81 their infants were the focus of this study. The intrapartum period was defined as within 2 days  
82 prior to or after delivery (11); the remaining antepartum period included the first, second and  
83 third trimesters as defined by GA  $< 12$  wk,  $\geq 12$  wk to  $< 28$  wk, and  $\geq 28$  wk, respectively.

84 To evaluate the performance of the Chembio DPP® ZCD IgM/IgG rapid test, convalescent-  
85 phase sera from RT-PCR-confirmed CHIKV cases (n=22) in Brazil served as CHIKV-positive  
86 reference samples (21) and CHIKV-negative reference samples (n=27) were from a dengue  
87 seroprevalence study in Taiwan (22), a CHIKV non-endemic country; both were confirmed by  
88 CHIKV pseudovirus neutralization test (NT). Convalescent-phase serum/plasma samples from  
89 RT-PCR-confirmed DENV (n=35) and ZIKV (n=42) cases were also included in the analysis  
90 (Table S1) (23).

91 The study of coded serum or plasma samples was approved by the Institutional Review  
92 Boards (IRB) of the Harvard Longwood Campus (IRB# 17-0654), University of Jos (IRB#  
93 127/XIX/5940), and University of Hawaii at Manoa (IRB# 2021-00044).

#### 94 **Isolation of viral RNA and RT-PCR**

95 Viral RNA was isolated from sera using the QIAamp viral RNA mini kit (Qiagen) and subjected to  
96 cDNA synthesis using the SuperScript™ III first-strand synthesis kit (Thermo Scientific); an  
97 aliquot of cDNA was subjected to nested PCR targeting a conserved region of the NSP2 gene of  
98 CHIKV (24). The RT-PCR products were electrophoresed through 2% agarose gel, and bands with  
99 the predicted size were purified for sequencing. The primers were CHIKV-F (5'-  
100 TCAATATGATGCAGATGAAAGT-3', position 2541-2562), CHIKV-inner R (5'-  
101 GTCACAGGCA GTGTACACC -3', position 2616-2634) and CHIKV-outer R (5'-  
102 GCAACGABGA CACAATGGC-3', position 2536-2654). The size of the 1<sup>st</sup> round and 2<sup>nd</sup> round  
103 products were 113 bp and 93 bp, respectively. The PCR protocol will be provided upon request.

104 **IgM and IgG enzyme-linked immunosorbent assays (ELISAs) using DENV and ZIKV**  
105 **mutated virus like particles (VLP)**

106 The plasmids expressing envelope protein fusion loop (FL)-mutated DENV1 VLP (Hawaii  
107 strain) and FL- and BC loop (BCL)-mutated ZIKV VLP (PRVABC59 strain), generation of  
108 VLP, and IgM and IgG ELISA using DENV FL-VLP or ZIKV FL/BCL VLP have been  
109 described previously (25). The sensitivity/specificity of DENV FL-VLP and ZIKV FL/BCL VLP  
110 IgG ELISAs was 100/93.3% and 100/83.3%, respectively; and that of DENV FL-VLP and ZIKV  
111 FL/BCL VLP IgM ELISAs was 75/95.8% and 90/99.3%, respectively.

### 112 **Microneutralization test**

113 Microneutralization test was performed as described previously (26,27). Briefly, flat-bottom 96-  
114 well plates were seeded with Vero cells ( $3 \times 10^4$  cells per well) 24 h prior to infection. Fourfold  
115 serial dilutions of serum (starting from 1:10 final dilution) were mixed with 50 focus-forming  
116 units of DENV1 (Hawaii strain), DENV2 (NGC strain), DENV3 (CH53489), DENV4 (H241  
117 strain), or ZIKV (PRVABC59 strain) at 37°C for 1 h. The mixtures were added to each well  
118 followed by incubation for 48 h (except 70 h for DENV1), removal of medium, and fixation as  
119 described previously (26,27). After adding a murine monoclonal antibody 4G2 and secondary  
120 antibody mixture (IRDye 800CW-conjugated goat anti-mouse IgG at 1:10,000 and DRAQ5  
121 fluorescent probe at 1:10,000), the signal (800 nm/700 nm fluorescence) was detected using a Li-  
122 Cor Odyssey Classic imaging system (Li-Cor Biosciences, Lincoln, NE) and analyzed using  
123 Image Studio software to determine percent neutralization at different concentrations and NT<sub>90</sub>  
124 as described previously (26,27).

### 125 **Cell lines and plasmids**

126 Human hepatoma Huh7 cells were obtained from Health Science Research Resources Bank,  
127 Japan Health Sciences Foundation (Osaka, Japan). HEK-293T cells were obtained from the  
128 American Type Culture Collection (Manassas, VA). Plasmids pNL4-3 R-E-miRFP, which

129 contains the monomeric infrared fluorescent protein (miRFP) gene replacing the Luc gene of an  
130 *env*-defective HIV-1 reporter construct pNL4-3.Luc.R-E-, has been described previously (28).  
131 The E3-E2-6K-E1 genes of CHIKV (2955 bp) and Mayaro virus (MAYV) (2952 bp) were PCR  
132 amplified from cDNA derived from RNA of CHIKV (H20235 strain) and MAYV (TRVL  
133 strain), respectively, (BEI Resources, Manassas, VA), and cloned into pCB vector (by NotI and  
134 XhoI sites) to generate plasmids CHIKV and MAYV. All plasmids were confirmed by  
135 sequencing of the entire E3-E2-6K-E1 gene insert and verified for expression by transfection and  
136 Western blot analysis (28).

### 137 **Generation of CHIKV and MAYV pseudoviruses**

138 To generate pseudoviruses, HEK-293T cells were seeded in 10-cm dish one day before  
139 transfection, co-transfected with pNL4-3 R-E-miRFP (12  $\mu$ g) and plasmids CHIKV (12  $\mu$ g) or  
140 MAYV (4  $\mu$ g) using lipofectamine 2000 and incubated with DMEM media containing 10% FBS  
141 (28). The supernatants were collected at 72 h post transfection, followed by low-speed  
142 centrifugation at 300x g for 10 min, aliquoted and stored at -80°C. To titrate each pseudovirus,  
143 3-fold serially diluted supernatants were inoculated to Huh7 cells by spin infection (28); miRFP  
144 signals were quantitated at 72 h post-infection, and the amount of pseudovirus that resulted in  
145 miRFP signals 10 times higher than the mock-infected wells was used for the NT.

### 146 **CHIKV and MAYV pseudovirus NT**

147 Huh7 cells ( $2 \times 10^4$  cells/well) were seeded onto 96-well plates one day before infection.  
148 Pseudovirus (CHIKV or MAYV) was mixed with 4-fold serial dilutions of plasma at 1:1 ratio,  
149 incubated at 37°C for 1 h, and added to each well for spin infection. At 72 h, the plates were  
150 scanned by Li-Cor Odyssey imager (28). The % of infection at different plasma dilutions (from  
151 1:10 to 1:10,240 dilutions) were calculated by the formula (intensity of serum+pseudovirus –

152 intensity of media only)/(intensity of pseudovirus only – intensity of media only) x 100. The %  
153 neutralization=100 – % of infection (28). NT<sub>50</sub> titer was the plasma dilution that reached 50%  
154 neutralization using 4-parameter nonlinear regression analysis (GraphPad 6.0, Boston, MA)  
155 (Figure 1). NT<sub>50</sub> titer<10 was arbitrarily assigned as 5.

## 156 **Statistical analysis**

157 The two-tailed Fisher's exact test (Pearson Chi-square test) and two-tailed Mann-Whitney test  
158 were used to compare qualitative and quantitative variables, respectively, between two groups;  
159 the two-tailed Wilcoxon signed-rank test paired data (GraphPad 6.0, Boston, MA).

## 160 **Results**

### 161 **Detection of CHIKV infection**

162 The Chembio DPP® ZCD IgM/IgG rapid test was used to detect CHIKV IgM and IgG in  
163 consenting pregnant women at the antenatal clinics of JUTH and OLA. To assess the  
164 sensitivity/specificity of the CHIKV IgM and IgG assays, we first tested with a panel of  
165 convalescent-phase samples from RT-PCR-confirmed CHIKV, DENV and ZIKV cases and  
166 CHIKV-negative samples from a dengue seroprevalence study in Taiwan (21-23). The  
167 sensitivity/specificity of the CHIKV IgM and IgG assays was 90.9/95.2% and 100/100%,  
168 respectively (Table S1).

169 Between April 2019 and January 2022, 787 febrile or otherwise symptomatic and 219  
170 asymptomatic women were screened. A third of women (312/1006, 31.0%) were reactive to  
171 ZIKV, DENV, CHIKV or some combination. CHIKV IgG was detected in 120/1006, suggesting  
172 a seroprevalence of 11.9%, and CHIKV IgM in 119/1006 (11.8%), suggesting acute or recent  
173 CHIKV infection. Among symptomatic women, headache was the most common symptom  
174 followed by fever and fatigue. Unlike similar studies in the Americas, rash and arthralgia were

175 not commonly reported. The prevalence of CHIKV IgM was higher in asymptomatic women  
176 (41/219, 18.7%) compared to symptomatic women (78/787, 9.9%). CHIKV RT-PCR was  
177 performed but none of the CHIKV IgM reactive samples tested positive.

### 178 **Confirmation of CHIKV infection by NT**

179 We further generated CHIKV pseudovirus based on a lentivirus vector with an miRFP  
180 reporter and developed a CHIKV NT (Figure 1) (28). When testing with a panel of convalescent-  
181 phase sera from RT-PCR-confirmed CHIKV cases in Brazil, we found high NT<sub>50</sub> titers (289-  
182 6867) to CHIKV (Figure 1). As a comparison, a MAYV pseudovirus NT was also performed and  
183 lower NT<sub>50</sub> titers (30-1522) to MAYV were observed; the ratio of CHIKV NT<sub>50</sub> titers to MAYV  
184 NT<sub>50</sub> titers were higher than 2.5, which was consistent with two recent reports (29,30).

185 We next used the CHIKV NT to examine 36 samples, collected during the first two years of  
186 the study, from 119 pregnant women with acute or recent CHIKV infection (either IgM+IgG+ or  
187 IgM+IgG-). Of the 36 samples, we found 18 with detectable neutralizing antibodies to CHIKV  
188 (16 from the IgM+IgG+ subgroup and 2 from the IgM+IgG- subgroup) (Table 1, Figure 2A).  
189 This is in agreement with the observation of distinct antibody patterns and the presence of an  
190 IgM+IgG- period in some individuals following CHIKV infection (31).

### 191 **Infant outcomes of antepartum CHIKV infection**

192 Of the 36 pregnant women with CHIKV IgM reactivity (either IgM+IgG+ or IgM+IgG-), 30  
193 were symptomatic suggesting acute CHIKV infection. Of the 30 women, 26 babies were  
194 followed up and 19 had normal and 7 had abnormal outcomes including three stillbirths, two  
195 multiple congenital anomalies, one polydactyly with sepsis and jaundice, and one preterm (Table  
196 1). In the subset of 14 acute CHIKV infections confirmed by NT, 12 babies were followed with 8  
197 normal and 4 abnormal outcomes.



198 The time course of 4 mothers with acute CHIKV infection confirmed by NT (Figures 2B-2E)  
199 and their babies with abnormal outcomes was summarized in Figures 3A-3D. Notably, babies  
200 with multiple congenital anomalies may have lower odds of survival. Case OL-ZP-0031 was  
201 enrolled at 39 wk with CHIKV IgM+/IgG- and NT<sub>50</sub> titer of 10 to CHIKV; she gave birth to a  
202 baby with multiple congenital anomalies including cleft lip, palate and microcephaly who passed  
203 away in 2 days (Figure 3A). Additionally, past flavivirus infection was confirmed by NT. Case  
204 OL-ZP-0028 was enrolled at 33 wk with CHIKV IgM+/IgG+ and high NT<sub>50</sub> titer (of 6657) to  
205 CHIKV; due to ZIKV ELISA IgG+, NT was performed and showed NT<sub>90</sub> titer of 51 to ZIKV  
206 and <10 to DENV1-4, suggesting past ZIKV infection (Figure 3D).

### 207 **Antepartum transmission of CHIKV**

208 Of the 26 CHIKV infections among symptomatic pregnant women with babies followed, one  
209 was detected in the first trimester, 8 second trimester and 17 third trimester (Table 2). We further  
210 examined the babies' samples to assess the possibility of antepartum transmission; of the 19  
211 available samples from babies followed, 3 were CHIKV IgM reactive (all in the third trimester  
212 with two normal and one preterm outcomes), suggesting antepartum transmission of CHIKV  
213 (Table 1). The time course of 3 pregnant women with antepartum CHIKV infection and  
214 transmission to their babies were summarized in Figures 3D and 3E-3F. Case OL-ZP-0028 gave  
215 birth to a preterm baby at 36 wk; the baby at 6 wk (the first follow-up) showed CHIKV  
216 IgM+/IgG+ (Figure 3D). Another past flavivirus infection confirmed by NT was noted in case  
217 OL-ZP-0020, who was enrolled at 37 wk with CHIKV IgM+/IgG+ and high NT<sub>50</sub> titer to  
218 CHIKV; due to ZIKV and DENV ELISAs IgG+, NT to ZIKV and DENV was performed and  
219 showed NT<sub>90</sub> titers of 163 to ZIKV, 39 to DENV2 and <10 to DENV1, 3 and 4, suggesting past

220 ZIKV and DENV infection. She gave birth to a normal baby at 40 wk; the baby followed up at  
221 day 1 showed CHIKV IgM+/IgG+ (Figure 3E).

## 222 **Discussion**

223 In this study, we examined CHIKV infection during pregnancy in a non-outbreak setting in  
224 Nigeria and reported antepartum transmission of CHIKV and association of antepartum CHIKV  
225 infection with abnormal infant outcomes.

226 Based on previous reports from the 2005 Reunion Island outbreak that MTCT of CHIKV  
227 occurred predominantly during the intrapartum period, subsequent studies of CHIKV infection  
228 during pregnancy primarily focused on the perinatal period and confirmed the contribution of  
229 intrapartum CHIKV infection to the MTCT of CHIKV with IOL and Asian genotypes in Asia and  
230 Latin America (14-19). Our finding of CHIKV transmission to 3 infants out of 19 (15.8%)  
231 pregnant women with antepartum CHIKV infection was unexpected compared with the Reunion  
232 Island study, in which 3 abortions out of 678 (0.4%) antepartum CHIKV infections were  
233 attributed to in utero CHIKV infection. The higher rates of antepartum CHIKV MTCT might be  
234 attributed to pathogenesis of endemic infection and/or CHIKV strain differences. Furthermore, we  
235 reported 7 abnormal infant outcomes including three stillbirths, two multiple congenital  
236 anomalies, one polydactyly with sepsis and jaundice, and one preterm associated with 26  
237 antepartum CHIKV infections (26.9%). The 7 abnormal infant outcomes were a subset of 17  
238 abnormal infant outcomes associated with arbovirus (ZIKV, DENV, and CHIKV) infection during  
239 pregnancy, in which birth registry data were compared (20). Notably, another study of the CHIKV  
240 outbreak in Colombo, Sri Lanka in 2006-2007 reported transmission of CHIKV to 6 infants  
241 (based on newborn IgM positivity) out of 46 (13.0 %) pregnant women with antepartum CHIKV  
242 infection and 10 (21.7%) abnormal outcomes including two abortions, one intrauterine death, one

243 preterm, five congenital heart diseases (atrial septal defect, patent ductus arteriosus and persistent  
244 foramen ovalis) and one intrauterine growth retardation (32). As the Sri Lanka outbreak was  
245 likely to be caused by the IOL, the difference between our findings and those from the Reunion  
246 Island outbreak could not be explained by different CHIKV genotypes alone.

247 A recent review of 13 CHIKV outbreaks in Africa from 1999 to 2020 revealed that viral  
248 lineage was identified in 8 outbreaks; all were associated with ECSA genotype (which the IOL  
249 originated from) except one outbreak of West African genotype in Kedougou, Senegal during  
250 2009-2010, in which 14 out of 144 acute sera at 5 health care facilities were confirmed by  
251 CHIKV RT-PCR and 6 CHIKV IgM+ cases were identified from 1409 sera collected (2,5,6).  
252 The timing of sample collection after symptom onset differed between studies and may account  
253 for the difference in detection by RT-PCR.

254 After CHIKV infection, individuals develop an IgM response starting from 3 to 8 days post-  
255 symptom onset, followed by an IgG response at 7 to 14 days (33-35). A recent study reported 5  
256 distinct antibody patterns (IgM-IgG-/NT-, IgM+IgG-/NT-, IgM+IgG-/NT+, IgM+IgG+/NT-  
257 and IgM+IgG+/NT+) during acute febrile phase and the presence of NT or IgG antibody was  
258 associated with protection against developing chronic arthritis in the future, which was supported  
259 by two studies of outbreaks in India (2010-3 and 2014-6) (31,36). Although most individuals of  
260 the IgM-IgG- and IgM+ IgG- subgroups developed IgG and NT antibodies at the convalescent-  
261 phase, this may explain some IgM+IgG- and NT- samples observed in our study.

262 The proportion of inapparent CHIKV infection has been reported to be 3%–25%,  
263 corresponding to a symptomatic to inapparent ratio of 1:0.03 to 1:0.33 (2,37). Recent studies of  
264 the outbreak in Nicaragua reported a higher proportion of inapparent infection with a  
265 symptomatic to inapparent ratio of 1:0.65 to 1:1.20, which varies between lineages and

266 epidemics (38,39). Our findings of a symptomatic to inapparent ratio of 1:2 is unexpected, which  
267 may be related to viral lineage differences and the non-outbreak setting.

268 Conventional plaque-reduction neutralization test (PRNT) for CHIKV requires a biosafety  
269 level 3 laboratory and is labor intensive and time-consuming (35). Several NTs based on  
270 different CHIKV pseudoviruses, replicon particles or genetically modified infectious clones  
271 containing luciferase or green fluorescent protein as reporters have been developed (40-44).  
272 Compared with live virus PRNT, our CHIKV pseudovirus NT can be performed in a biosafety  
273 level 2 laboratory and requires fewer plates (one 96-well plate for 6 samples in duplicates vs.  
274 eighteen 6-well plates for PRNT), less time (72 h vs. >4 days for PRNT), and less sample  
275 volume (20  $\mu$ L vs. 100  $\mu$ L for PRNT in duplicates, starting from serum at 1:10 final dilution).  
276 Compared with CHIKV pseudoviruses using luciferase reporter, our CHIKV pseudovirus  
277 employed miRFP reporter which can be quantified by one step of direct imaging without  
278 multiple laborious steps (5 min scan vs. ~60 min for a 96-well plate) (Figure 1). Moreover, the  
279 same plate can be quantified multiple times for kinetic study without generating numerous  
280 replicates. Compared with GFP reporter, miRFP has minimal autofluorescence and can be  
281 quantified by either direct imaging or flow cytometry to determine the percentage of positive  
282 cells. Together, these features suggest our CHIKV pseudovirus with miRFP reporter is a simple,  
283 practical, and cost-effective tool for neutralization.

284 There are several limitations to our study. First, the sample size of pregnant women with  
285 CHIKV infection (IgM+) analyzed (n=36) was small; future studies involving larger sample size  
286 are needed to validate these observations. There was no difference in age, ethnic groups,  
287 trimesters, and ratio of symptomatic vs. inapparent infection between the 36 pregnant women  
288 analyzed and the 83 pregnant women not analyzed in this study (Pearson Chi-square test), except

289 that the 36 women were enrolled exclusively during the first two years of the study. Therefore,  
290 the analysis of this subset was unlikely to affect our results. Second, although the babies'  
291 samples after delivery or the first follow-up were assessed to identify antepartum transmission,  
292 the possibility of neonate CHIKV infection cannot be completely ruled out. For example, the  
293 first available follow-up sample for the baby of case OL-ZP-0015 was at 14 wk (Figure 3F);  
294 excluding this case resulted in an antepartum transmission rate of 10.5% (2/19), which was still  
295 higher than that (0.4%) reported in the Reunion Island study. Third, NT to rule out O'nyong-  
296 nyong virus (ONNV), a closely related alphavirus which caused intermittent yet explosive  
297 outbreaks in East Africa, was not performed (35,45). Despite previous report of the  
298 unidirectional antigenic relationships between the two viruses, some sera still cannot be  
299 distinguished by NT (46-49). Since the ONNV outbreak involving both the East and West Africa  
300 in 1959-1962, ONNV has been apparently silent for 35 years until 1996-1997 when another  
301 outbreak in East Africa (Uganda and Kenya and Tanzania) took place (45,48-50). In Nigeria,  
302 only 3 confirmed-ONNV cases (by virus isolation) were reported in 1966 and 1969, suggesting  
303 the possibility of ONNV infection among the participants in Nigeria is remote (45).

304 CHIKV was first described in Africa, yet subsequent to the Reunion Island outbreak the  
305 epidemiology and pathogenesis in the continent has been infrequently studied. Our study  
306 provides new and convenient diagnostic tools for future study. In addition, we describe  
307 significant asymptomatic infection and abnormal pregnancy and infant outcomes associated with  
308 antepartum CHIKV infection. Future studies are needed to further characterize the risk of  
309 antepartum CHIKV infection to pregnant women and their infants in Africa.

310

311 **Supplementary Data**

312 Appendix Table 1 and Figure 1.

313

### 314 **Acknowledgments**

315 We thank the pregnant women at the JUTH and OLA clinics that participated in this study to  
316 advance our knowledge of arbovirus infection. We also thank the clinical, laboratory and data  
317 management teams at JUTH and OLA whose efforts enabled this work. This work was  
318 supported by grants R21AI137840 (Kanki) and R01AI149502-03 (Wang) from the National  
319 Institute of Allergy and Infectious Diseases, 5D43TWO10130 (Sagay) from the Fogarty  
320 International Center, NIH, and MedRes-2022-0000 0789 (Wang) from the Hawaii Community  
321 Foundation. The funders had no role in study design, data collection and analysis, decision to  
322 publish, or preparation of the manuscript.

323

### 324 **About the Author**

325 Dr. Atiene Sagay is a Professor of Obstetrics and Gynecology at the University of Jos, Nigeria,  
326 his research centers on maternal health. Dr. Szu-Chia Hsieh was a Research Scientist at the  
327 Department of Tropical Medicine, Medical Microbiology and Pharmacology at the University of  
328 Hawaii at Manoa during this study and is currently relocated to the Graduate Institute of  
329 Anatomy and Cell Biology, College of Medicine, National Taiwan University; her research  
330 focuses on arboviruses. Ms. Yu-Ching Dai was a Research Assistant and currently Graduate  
331 student at the Department of Tropical Medicine, Medical Microbiology and Pharmacology at the  
332 University of Hawaii at Manoa; her research focuses on arboviruses.

## 333 **References**

- 334 1. Weaver SC, Lecuit M. Chikungunya virus and the global spread of a mosquito-borne  
335 disease. *N Engl J Med*. 2015;372:1231-9.
- 336 2. Bettis AA, L'Azou Jackson M, Yoon IK, Breugelmans JG, Goios A, Gubler DJ, et al. The  
337 global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to  
338 inform the development and introduction of vaccines. *PLoS Negl Trop Dis*.  
339 2022;16:e0010069.
- 340 3. Puntasecca CJ, King CH, LaBeaud AD. Measuring the global burden of chikungunya and  
341 Zika viruses: A systematic review. *PLoS Negl Trop Dis*. 2021;15:e0009055.
- 342 4. Pezzi L, Reusken CB, Weaver SC, Drexler JF, Busch M, LaBeaud AD, et al. GloPID-R  
343 report on Chikungunya, O'nyong-nyong and Mayaro virus, part I: Biological diagnostics.  
344 *Antiviral Res*. 2019;166:66-81.
- 345 5. Sow A, Faye O, Diallo M, Diallo D, Chen R, Faye O, et al. Chikungunya Outbreak in  
346 Kedougou, Southeastern Senegal in 2009-2010. *Open Forum Infect Dis*. 2017;5:ofx259.
- 347 6. Althouse BM, Guerbois M, Cummings DAT, Diop OM, Faye O, Faye A, et al. Role of  
348 monkeys in the sylvatic cycle of chikungunya virus in Senegal. *Nat Commun*. 2018;9:1046.
- 349 7. Renault P, Solet JL, Sissoko D, Balleydier E, Larrieu S, Filleul L, et al. A major epidemic of  
350 chikungunya virus infection on Reunion Island, France, 2005-2006. *Am J Trop Med Hyg*.  
351 2007;77:727-31.
- 352 8. Peyrefitte CN, Bessaud M, Pastorino BA, Gravier P, Plumet S, Merle OL, et al. Circulation  
353 of Chikungunya virus in Gabon, 2006-2007. *J Med Virol*. 2008;80:430-3.
- 354 9. Charlier C, Beaudoin MC, Couderc T, Lortholary O, Lecuit M. Arboviruses and pregnancy:  
355 maternal, fetal, and neonatal effects. *Lancet Child Adolesc Health*. 2017;1:134-46.

- 356 10. Contopoulos-Ioannidis D, Newman-Lindsay S, Chow C, LaBeaud AD. Mother-to-child  
357 transmission of chikungunya virus: A systematic review and meta-analysis. *PLoS Negl Trop*  
358 *Dis.* 2018;12:e0006510.
- 359 11. Gérardin P, Barau G, Michault A, Bintner M, Randrianaivo H, Choker G, et al.  
360 Multidisciplinary prospective study of mother-to-child chikungunya virus infections on the  
361 island of La Réunion. *PLoS Med.* 2008;5:e60.
- 362 12. Fritel X, Rollot O, Gerardin P, Gauzere BA, Bideault J, Lagarde L, et al. Chikungunya  
363 virus infection during pregnancy, Reunion, France, 2006. *Emerg Infect Dis.* 2010;16:418-25.
- 364 13. Ramful D, Sampériz S, Fritel X, Michault A, Jaffar-Bandjee MC, Rollot O, et al. Antibody  
365 kinetics in infants exposed to chikungunya virus infection during pregnancy reveals absence  
366 of congenital infection. *J Infect Dis.* 2014;209:1726-30.
- 367 14. Kumar S, Agrawal G, Wazir S, Kumar A, Dubey S, Balde M, et al. Experience of perinatal  
368 and neonatal chikungunya virus (Chikv) infection in a tertiary care neonatal centre during  
369 outbreak in North India in 2016: a case series. *J Trop Pediatr.* 2019;65:169-75.
- 370 15. Villamil-Gomez W, Alba-Silvera L, Menco-Ramos A, Gonzalez-Vergara A, Molinares-  
371 Palacios T, Barrios-Corrales M, et al. Congenital chikungunya virus infection in Sincelejo,  
372 Colombia: a case series. *J Trop Pediatr.* 2015;61:386-92.
- 373 16. Bandeira AC, Campos GS, Sardi SI, Rocha VF, Rocha GC. Neonatal encephalitis due to  
374 chikungunya vertical transmission: first report in Brazil. *ID Cases.* 2016;5:57-9.
- 375 17. van Enter BJD, Huibers MHW, van Rooij L, Steingrover R, van Hensbroek MB, Voigt RR,  
376 et al. Perinatal outcomes in vertically infected neonates during a chikungunya outbreak on the  
377 Island of Curacao. *Am J Trop Med Hyg.* 2018;99:1415-8.



- 378 18. Torres JR, Falleiros-Arlant LH, Dueñas L, Pleitez-Navarrete J, Salgado DM, Castillo JB.  
379 Congenital and perinatal complications of chikungunya fever: a Latin American experience.  
380 *Int J Infect Dis.* 2016;51:85-88.
- 381 19. Escobar M, Nieto AJ, Loaiza-Osorio S, Barona JS, Rosso F. Pregnant women hospitalized  
382 with chikungunya virus infection, Colombia, 2015. *Emerg Infect Dis.* 2017;23:1777-83.
- 383 20. Ogwuche J, Chang CA, Ige O, Sagay AS, Chaplin B, Kahansim ML, et al. Arbovirus  
384 surveillance in pregnant women in north-central Nigeria, 2019-2022. submitted. 2023.
- 385 21. de Moraes L, Cerqueira-Silva T, Nobrega V, Akrami K, Santos LA, Orge C, et al. A  
386 clinical scoring system to predict long-term arthralgia in chikungunya disease: A cohort  
387 study. *PLoS Negl Trop Dis.* 2020;14(7):e0008467.
- 388 22. Tsai JJ, Liu CK, Tsai WY, Liu LT, Tyson J, Tsai CY, et al. Seroprevalence of dengue in  
389 two districts of Kaohsiung city after the largest dengue outbreak in Taiwan since world war  
390 II. *PLoS Negl Trop Dis* 2018;12:e0006879.
- 391 23. Tyson J, Tsai WY, Tsai JJ, Brites C, Mässgård L, Youn HH, et al. Combination of non-  
392 structural protein 1-based enzyme-linked immunosorbent assays can detect and distinguish  
393 various dengue virus and Zika virus infections. *J Clin Microbiol.* 2019;57: e01464-18.
- 394 24. Waggoner JJ, Ballesteros G, Gresh L, Mohamed-Hadley A, Tellez Y, Sahoo MK, et al.  
395 Clinical evaluation of a single-reaction real-time RT-PCR for pan-dengue and chikungunya  
396 virus detection. *J Clin Virol.* 2016;78:57-61.
- 397 25. Tsai WY, Driese K, Tsai JJ, Granat RS, Jenkins O, Hsieh SC, et al. Enzyme-linked  
398 immunosorbent assays using virus-like particles containing mutations of conserved residues  
399 on envelop protein can distinguish three flavivirus infections. *Emerg Microbe Infect*  
400 2020;9:1722-32.

- 401 26. Tsai WY, Chen HL, Tsai JJ, Dejnirattisai W, Jumnainsong A, Mongkolsapaya J, et al.  
402 Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus  
403 particles: implication for novel strategy of dengue vaccine. *J Virol.* 2018;92:e00556-18.
- 404 27. Herrera BB, Tsai WY, Brites C, Luz E, Pedroso C, Drexler JF, et al. T cell responses to  
405 nonstructural protein 3 distinguish infections by dengue and Zika viruses. *mBio* 2018;9:  
406 e00755-18.
- 407 28. Tsai WY, Ching LC, Hsieh SC, Melish ME, Nerriah VR, Wang WK. A real-time and high-  
408 throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric  
409 infrared fluorescent protein as reporter. *Emerg Microbe Infect.* 2021;10:894-905.
- 410 29. Martins KA, Gregory MK, Valdez SM, Sprague TR, Encinales L, Pacheco N, et al.  
411 Neutralizing antibodies from convalescent chikungunya virus patients can cross-  
412 neutralize Mayaro and Una viruses. *Am J Trop Med Hyg.* 2019;100:1541-44.
- 413 30. Bopp NE, Jencks KJ, Siles C, Guevara C, Vilcarrromero S, Fernández D, et al. Serological  
414 responses in patients infected with Mayaro virus and evaluation of cross-protective responses  
415 against chikungunya virus. *Am J Trop Med Hyg.* 2021;106:607-9.
- 416 31. Nayak K, Jain V, Kaur M, Khan N, Gottimukkala K, Aggarwal C, et al. Antibody response  
417 patterns in chikungunya febrile phase predict protection versus progression to chronic  
418 arthritis. *JCI Insight.* 2020;5:e130509.
- 419 32. Senanayake MP, Senanayake SM, Vidanage KK, Gunasena S, Lamabadusuriya SP.  
420 Vertical transmission in chikungunya infection. *Ceylon Med J.* 2009;54:47-50.
- 421 33. Chua CL, Sam IC, Chiam CW, Chan YF. The neutralizing role of IgM during  
422 early chikungunya virus infection. *PLoS One.* 2017;12:e0171989.

- 423 34. Patil HP, Gosavi M, Kulkarni R, Mishra AC, Arankalle VA. Immunoglobulin G subclass  
424 response after chikungunya virus infection. *Viral Immunol.* 2022;35:437-42.
- 425 35. Griffin DE. 2013. Chapter 23 Alphaviruses. Knipe DM, Howley PM, eds. *Fields virology*,  
426 6th ed, Philadelphia: Lippincott William & Wilkins. pp 651-686.
- 427 36. Jain J, Nayak K, Tanwar N, Gaiind R, Gupta B, Shastri JS, et al. Clinical, serological, and  
428 virological analysis of 572 chikungunya patients from 2010 to 2013 in India. *Clin Infect Dis.*  
429 2017;65:133-40.
- 430 37. Staples JE, Breiman RF, Powers AM. Chikungunya fever: an epidemiological review of a  
431 re-emerging infectious disease. *Clin Infect Dis.* 2009;49:942-8.
- 432 38. Bustos Carrillo F, Collado D, Sanchez N, Ojeda S, Lopez Mercado B, Burger-Calderon R,  
433 et al. Epidemiological evidence for lineage-specific differences in the risk of  
434 inapparent chikungunya virus infection. *J Virol.* 2019;93:e01622-18.
- 435 39. Gordon A, Gresh L, Ojeda S, Chowell G, Gonzalez K, Sanchez N, et al. Differences in  
436 transmission and disease severity between 2 successive waves of chikungunya. *Clin Infect*  
437 *Dis.* 2018;67:1760-7.
- 438 40. Kishishita N, Takeda N, Anuegoonpipat A, Anantapreecha S. Development of a  
439 pseudotyped-lentiviral-vector-based neutralization assay for chikungunya virus infection. *J*  
440 *Clin Microbiol.* 2013;51:1389-95.
- 441 41. Henss L, Yue C, Kandler J, Faddy HM, Simmons G, Panning M, et al. Establishment of an  
442 alphavirus-specific neutralization assay to distinguish infections with different members of  
443 the Semliki Forest complex. *Viruses.* 2019;11:82.
- 444 42. Su C, Ding K, Xu J, Wu J, Liu J, Shen J, et al. Preparation and application of  
445 chi pseudovirus containing double reporter genes. *Sci Rep.* 2022;12:9844.

- 446 43. Deng CL, Liu SQ, Zhou DG, Xu LL, Li XD, Zhang PT, et al. Development  
447 of neutralization assay using an eGFP chikungunya virus. *Viruses*. 2016;8:181.
- 448 44. Schmidt C, Perkovic M, Schnierle BS. Development of a sensitive detection method for  
449 alphaviruses and its use as a virus neutralization assay. *Viruses*. 2021;13:1191.
- 450 45. Pezzi L, LaBeaud AD, Reusken CB, Drexler JF, Vasilakis N, Diallo M, et al. GloPID-R  
451 chikungunya, o'nyong-nyong and Mayaro virus Working Group. GloPID-R report  
452 on chikungunya, o'nyong-nyong and Mayaro virus, part 2: Epidemiological distribution of  
453 o'nyong-nyong virus. *Antiviral Res*. 2019;172:104611.
- 454 46. Chanas AC, Hubalek Z, Johnson BK, Simpson DI. A comparative study of O'nyong nyong  
455 virus with chikungunya virus and plaque variants. *Arch Virol*. 1979;59:231-8.
- 456 47. Henss L, Yue C, Von Rhein C, Tschismarov R, Lewis-Ximenez LL, Dölle A, et al.  
457 Analysis of humoral immune responses in chikungunya virus (CHIKV)-infected patients and  
458 individuals vaccinated with a candidate CHIKV vaccine. *J Infect Dis*. 2020;221:1713-23.
- 459 48. Clements TL, Rossi CA, Irish AK, Kibuuka H, Eller LA, Robb ML, et al. Chikungunya and  
460 O'nyong-nyong viruses in Uganda: implications for diagnostics. *Open Forum Infect Dis*.  
461 2019;6:ofz001.
- 462 49. LaBeaud AD, Banda T, Brichard J, Muchiri EM, Mungai PL, Mutuku FM, et al. High rates  
463 of o'nyong nyong and chikungunya virus transmission in coastal Kenya. *PLoS Negl Trop*  
464 *Dis*. 2015;9:e0003436.
- 465 50. Shah MM, Ndenga BA, Mutuku FM, Okuta V, Ronga CO, Chebii PK, et al. No Evidence  
466 of O'nyong-nyong viremia among children with febrile illness in Kenya (2015-2018). *Am J*  
467 *Trop Med Hyg*. 2021;104:1435-7.
- 468

469

470

471 **Table 1.** Serological evidence of CHIKV infection during pregnancy and infant outcomes

CHIKV Serological tests*	Pregnant women n=36	Symptomatic pregnant women n=30	Infants follow-up n=26	Infant outcomes	
				normal n=19	abnormal n=7
IgM+IgG-	17	15			
NT+	2	2	2	0	1 multiple congenital anomalies (cleft lip/palate/microcephaly) 1 polydactyly/sepsis/jaundice
NT-	15	13	11	8	1 stillbirth 1 stillbirth and preterm 1 multiple congenital anomalies (hypotonia/seizure/microcephaly)
IgM+IgG+	19	15			
NT+	16	12	10	8 (2 antepartum transmission)	1 stillbirth 1 preterm (antepartum transmission)
NT-	3	3	3	3	0

472

473

474

475

476

477

\* Chembio DPP® ZCD IgM/IgG rapid test was performed to detect CHIKV IgM and IgG, followed by CHIKV pseudovirus neutralization test (NT).

**Table 2.** Time of CHIKV infection during pregnancy and infant outcomes

CHIKV Serological tests*	Pregnant women n=36	Symptomatic pregnant women n=30	Infants follow-up n=26	CHIKV infection during pregnancy			
				1 <sup>st</sup> trimester n=1	2 <sup>nd</sup> trimester n=8	3 <sup>rd</sup> trimester prior to labor n=17	intrapartum n=0
IgM+ IgG-	17	15					
NT+	2	2	2	0	1 (†)	1 (¶)	0
NT-	15	13	11	1	4	6 (\$‡§)	0
IgM+ IgG+	19	15					
NT+	16	12	10	0	1	9 (‡#)	0
NT-	3	3	3	0	2	1	0

478

479

480

481

482

483

484

485

486

487

488

489

\* Chembio DPP® ZCD IgM/IgG rapid test was performed to detect CHIKV IgM and IgG, followed by CHIKV pseudovirus neutralization test (NT).

Infants with abnormal outcomes are shown in parenthesis:

† polydactyly/sepsis/jaundice.


¶ multiple congenital anomalies (cleft lip/palate/microcephaly).

\$ multiple congenital anomalies (hypotonia/seizure/microcephaly).

‡ stillbirth.

§ stillbirth and preterm. The time course of 3 pregnant women with acute CHIKV infection not confirmed by NT and their infants with abnormal outcomes was summarized in Appendix Figure 1.


# preterm.



490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505

**Figure 1.** Generation of CHIKV and MAYV pseudoviruses and NT.


(A) Schematic drawing of plasmids expressing E2 and E1 proteins (E3-E2-6K-E1 genes) of CHIKV or MAYV and co-transfection with pNL43 R-E-miRFP (miRFP) to generate CHIKV or MAYV pseudoviruses containing miRFP reporter, infection of target cells and one-step imaging. (B) NTs based on CHIKV and MAYV pseudoviruses with miRFP reporter. The miRFP signals (left) and neutralization curves and NT<sub>50</sub> titers (right) to CHIKV and MAYV pseudoviruses at 72 h post-infection in Huh7 cells of convalescent-phase serum sample from an RT-PCT-confirmed CHIKV case from Brazil. (C) Neutralization curves and NT<sub>50</sub> titers to CHIKV and MAYV pseudoviruses of other 2 confirmed CHIKV cases. (D) NT<sub>50</sub> titers to CHIKV and MAYV pseudoviruses of 22 confirmed CHIKV cases and 27 CHIKV-negative individuals. The two-tailed Mann-Whitney (left) and Wilcoxon signed-rank (right) tests (GraphPad 6.0).



506  
507  
508  
509  
510  
511  
512  
513

**Figure 2.** CHIKV pseudoviruses NT in Nigeria pregnant women. (A) CHIKV NT<sub>50</sub> titers in different subgroups based on CHIKV IgM/IgG results using Chembio DPP® ZCD IgM/IgG rapid test. (B-E) Neutralization curves and NT<sub>50</sub> titers to CHIKV and MAYV pseudoviruses of 4 pregnant women with acute CHIKV infection and abnormal infant outcomes. Data are means and standard deviations of duplicates from one experiment.

514



515

516

517 **Figure 3.** Time course of pregnant women who had acute CHIKV infection confirmed by NT  
 518 and gave birth to babies with abnormal outcomes or antepartum transmission. (A-D) Time course  
 519 of 4 pregnant women with acute CHIKV infection and abnormal infant outcomes. Multiple  
 520 congenital anomalies with cleft lip/palate and microcephaly (A), stillbirths (B),  
 521 polydactyly/sepsis/ jaundice (C), and preterm (D). (D, E-F) Time course of 3 pregnant women  
 522 with acute CHIKV infection and antepartum transmission of CHIKV to fetus. GA, gestational  
 523 age; wk, weeks; Z, Zika virus; D, dengue virus; C, chikungunya virus. CHIKV IgM-reactive  
 524 infants highlighted in red.